{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:50:10Z","timestamp":1792007410177,"version":"4.4.0"},"reference-count":120,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Allogeneic hematopoietic cell transplantation (alloHCT) is the sole curative therapy for myelodysplastic syndrome (MDS). While alloHCT clearly confers a significant survival advantage in high-risk MDS, it is less clear how the disease burden and impact of conditioning intensity impact survival. This review addresses critical issues surrounding this topic, emphasizing the unique cell biology of MDS and the evolving concepts of conditioning intensity compared to other diseases, including acute myeloid leukemia (AML). The review is structured around three interconnected themes. First, it clarifies the varying interpretations of conditioning intensity. Second, it examines the interplay between disease burden at transplant and conditioning intensity in determining outcomes, including a comparative analysis with acute myeloid leukemia (AML) to highlight similarities and differences. Third, it explores the relationship between conditioning regimen intensity and immune reconstitution, particularly focusing on the graft-versus-tumor (GvT) effect and its potential modulation by conditioning intensity. Understanding the stem cell target of conditioning regimens is emphasized, as the persistence of the underlying MDS stem cell necessitates a thorough understanding of this concept for improved therapeutic strategies.<\/jats:p>","DOI":"10.3390\/curroncol32060319","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:14:27Z","timestamp":1748585667000},"page":"319","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS)"],"prefix":"10.3390","volume":"32","author":[{"given":"Tobias","family":"Berg","sequence":"first","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Salter","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, McMaster University, Hamilton, ON L8V 5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9562-2029","authenticated-orcid":false,"given":"Michael","family":"Radford","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He Tian Tony","family":"Chen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-1480","authenticated-orcid":false,"given":"Brian","family":"Leber","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, McMaster University, Hamilton, ON L8V 5C2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jtct.2022.11.014","article-title":"Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines","volume":"29","author":"DeFilipp","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50\u201375 Years of Age with Advanced Myelodysplastic Syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity","volume":"176","author":"Hovestadt","year":"2019","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","article-title":"A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy","volume":"13","author":"Pei","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.stem.2023.04.001","article-title":"Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia","volume":"30","author":"Merbach","year":"2023","journal-title":"Cell Stem Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/1878-0261.13606","article-title":"An arms-race against resistance: Leukemic stem cells and lineage plasticity","volume":"18","author":"Waclawiczek","year":"2024","journal-title":"Mol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-024-01571-4","article-title":"A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC","volume":"17","author":"Xiao","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_11","unstructured":"Kewan, T. (2025, April 10). Clinical and Molecular Insights into the Classification Dilemma: Are MDS\/AML Cases Distinct from Secondary AML? ASH. Available online: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper207770.html."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sureda, A., Corbacioglu, S., Greco, R., Kr\u00f6ger, N., and Carreras, E. (2024). The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies, Springer International Publishing. Available online: https:\/\/link.springer.com\/10.1007\/978-3-031-44080-9.","DOI":"10.1007\/978-3-031-44080-9"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in current era: A study in acute myeloid leukemia patients","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3324\/haematol.2020.268839","article-title":"Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: Can we recommend \u201cwhen and for whom\u201d in 2021?","volume":"106","author":"Gagelmann","year":"2021","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients with Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)","volume":"35","author":"Iacobelli","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e18501","DOI":"10.1200\/JCO.2016.34.15_suppl.e18501","article-title":"Hematopoietic stem cell transplantation (HSCT) compared to consolidation chemotherapy (CT) to increase leukemia free survival (LFS) in acute myelogenous leukemia (AML) patients between 60 and 75 years irrespective of genetic risk: Report from the AML 2004 of the East German Study Group (OSHO)","volume":"34","author":"Niederwieser","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41586-022-04786-y","article-title":"Clonal dynamics of haematopoiesis across the human lifespan","volume":"606","author":"Mitchell","year":"2022","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2019.12.725","article-title":"Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study","volume":"26","author":"Sora","year":"2020","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"921.e1","DOI":"10.1016\/j.jtct.2021.08.007","article-title":"Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes","volume":"27","author":"Oran","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjh.15137","article-title":"High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia","volume":"180","author":"Steckel","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): A randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41409-023-02111-3","article-title":"Sequential vs. reduced intensity conditioning for apteits with myelodysplastic syndromes with an excess of blasts at time of allogeneic hematopoietic cell transplantation: A retrospective study by the chronic malignancies working party of the EBMT","volume":"59","author":"Potter","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","article-title":"Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): A randomised, non-inferiority, phase 3 trial","volume":"7","author":"Beelen","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sureda, A., Corbacioglu, S., Greco, R., Kr\u00f6ger, N., and Carreras, E. (2024). Conditioning. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies, Springer International Publishing.","DOI":"10.1007\/978-3-031-44080-9"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"681.e1","DOI":"10.1016\/j.jtct.2024.04.014","article-title":"Treosulfan-Versus Busulfan-based Conditioning in Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Single-center Retrospective Propensity Score-matched Cohort Study","volume":"30","author":"Pasic","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","article-title":"Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ajh.26620","article-title":"Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic patients: Final analysis of a prospective randomized trial","volume":"97","author":"Bellen","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2016.05.026","article-title":"Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research","volume":"22","author":"Potter","year":"2016","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/ajh.25636","article-title":"Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes","volume":"94","author":"Jentzsch","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Walter, R.B., Potter, V., and Craddock, C. (2024). Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Adults over 70 years old. Blood.","DOI":"10.1182\/blood.2024024247"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2013-12-542720","article-title":"Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R","volume":"123","author":"Alessandrino","year":"2014","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3324\/haematol.2018.200808","article-title":"Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation","volume":"104","author":"Gagelmann","year":"2019","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.23.02175","article-title":"Clinical and Genomic-based decision support to define optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndrome","volume":"42","author":"Tentori","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"106645","DOI":"10.1016\/j.leukres.2021.106645","article-title":"Pre-transplant therapy for patients with myelodysplastic syndromes: A systematic review and meta-analysis","volume":"110","author":"Wang","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bbmt.2018.08.004","article-title":"Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome","volume":"25","author":"Park","year":"2019","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"12342","DOI":"10.18632\/oncotarget.12511","article-title":"Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts","volume":"8","author":"Yahng","year":"2017","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.13576","article-title":"Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation","volume":"171","author":"Symeonidis","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbmt.2008.10.012","article-title":"Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: Importance of pretransplant disease burden","volume":"15","author":"Warlick","year":"2009","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1182\/blood.V98.8.2326","article-title":"Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS","volume":"98","author":"Suciu","year":"2001","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"E188","DOI":"10.1002\/ajh.25490","article-title":"Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts","volume":"94","author":"Strati","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_45","first-page":"1997","article-title":"Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia","volume":"100","author":"Sierra","year":"2002","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.bbmt.2019.03.011","article-title":"Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia","volume":"25","author":"Schroeder","year":"2019","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41409-024-02365-5","article-title":"Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome","volume":"59","author":"Schroeder","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.23.01159","article-title":"Patient-specific measurable disease markers predict outcome in patients with myelodysplastic syndrome and related disorders after hematopoietic stem-cell transplantation","volume":"42","author":"Tobiasson","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hon.2566","article-title":"Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis","volume":"37","author":"Konuma","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ijc.33608","article-title":"Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with MDS-EB-1 or MDS-EB-2","volume":"149","author":"Chen","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3324\/haematol.2014.106880","article-title":"Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: A retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party","volume":"99","author":"Onida","year":"2014","journal-title":"Haematologica"},{"key":"ref_52","unstructured":"Rolles, B. (2025, February 07). Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes\/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database. ASH. Available online: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper208034.html."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.2023022273","article-title":"Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic syndrome?","volume":"144","author":"Scheid","year":"2024","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood.2024024824","article-title":"Change is not always good","volume":"144","author":"Scott","year":"2024","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.annonc.2020.11.002","article-title":"Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Fenaux","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: Recommendations from an international expert panel","volume":"129","author":"Bowen","year":"2017","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1200\/JCO.2012.44.3499","article-title":"Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: A study by the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie-Cellulaire and the Groupe-Francophone des My\u00e9lodysplasies","volume":"30","author":"Damaj","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.leu.2403640","article-title":"Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome","volume":"19","author":"Nakai","year":"2005","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients with Advanced MDS According to Donor Availability (VidazaAllo Study)","volume":"39","author":"Sockel","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/hematology.2021000257","article-title":"Allogeneic hematopoietic cell transplantation for older patients","volume":"2021","author":"Lin","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","article-title":"Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients with Myelodysplastic Syndromes Treated with Allogeneic Hematopoietic Stem-Cell Transplantation","volume":"34","author":"Bacigalupo","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: Impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/bloodadvances.2020003508","article-title":"Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes","volume":"5","author":"Hunter","year":"2021","journal-title":"Blood Adv."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1200\/JCO.23.00866","article-title":"Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study","volume":"41","author":"Versluis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","article-title":"Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine","volume":"38","author":"Bally","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2024.04.004","article-title":"Putting the STING back into BH3-mimetic drugs for T53-mutant blood cancers","volume":"42","author":"Diepstraten","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1016\/S2152-2650(22)01230-7","article-title":"AML-147 C_MYC targeting by degradation: Novel dual Myc\/GSTP1 degrader GT19715 exerts profound cell kill in vitro and in vivo in acute myeloid leukemia and lymphomas","volume":"22","author":"Nishida","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood-2019-131530","article-title":"Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation","volume":"134","author":"Chan","year":"2019","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Scott, B.L. (2020). Long-Term Follow up of BMT CTN 0901, a Randomized Phase III Trial Comparing Myeloablative (MAC) to Reduced Intensity Conditioning (RIC) Prior to Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) (MAvRIC Trial). Biol. Blood Marrow Transplant., 26.","DOI":"10.1016\/j.bbmt.2019.12.075"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2021-154151","article-title":"Non-Relapse Mortality in TP53-Mutated MDS\/AML\u2014A Multi-Center Collaborative Study","volume":"138","author":"Byrne","year":"2021","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as Post-Transplant Maintenance for AML with Internal Tandem Duplication Mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_78","unstructured":"Sallman, D., Garcia-Manero, G., Daver, N., Aboud, C., Stein, E., Larkin, K., Halpern, A., McCurdy, S., Al Malki, M., and Murthy, G. (2024). Magrolimab + azacytidine vs. placebo + azacytidine in patients with untreated high-risk myelodysplastic syndrome: Phase 3 ENHANCE study final analysis. EHA Libr., S181."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","article-title":"Mutation Clearance after Transplantation for Myelodysplastic Syndrome","volume":"379","author":"Duncavage","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41375-020-0997-4","article-title":"Prognostic Significance of Serial Molecular Annotation in Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)","volume":"35","author":"Yun","year":"2021","journal-title":"Leukemia"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Hou, C., Zhou, L., Yang, M., Jiang, S., Shen, H., Zhu, M., Chen, J., Miao, M., Xu, Y., and Wu, D. (2021). The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.700234"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/cncr.34762","article-title":"Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort study","volume":"129","author":"Ma","year":"2023","journal-title":"Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.bbmt.2016.03.029","article-title":"Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome","volume":"22","author":"Festuccia","year":"2016","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/PO.20.00355","article-title":"Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients with Myelodysplastic Syndrome","volume":"5","author":"Dillon","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia with Genomic Evidence of Residual Disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"32","author":"Dillon","year":"2023","journal-title":"JAMA"},{"key":"ref_87","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2024.11.006","article-title":"Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS","volume":"31","author":"Radford","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.bbmt.2015.07.005","article-title":"Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"21","author":"Lee","year":"2015","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/blood-2004-04-1506","article-title":"Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"104","author":"Baron","year":"2004","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nri2200","article-title":"Specificity of T-cell alloreactivity","volume":"7","author":"Felix","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"646","DOI":"10.7326\/0003-4819-120-8-199404150-00004","article-title":"Identical-twin bone marrow transplants for leukemia","volume":"120","author":"Gale","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bmt.1705648","article-title":"Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: A retrospective study including 148 patients","volume":"39","author":"Heining","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Dekker, L., de Koning, C., Lindemans, C., and Nierkens, S. (2020). Reconstitution of T Cell Subsets Following Allogeneic Hematopoietic Cell Transplantation. Cancers, 12.","DOI":"10.3390\/cancers12071974"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1182\/blood-2015-12-629055","article-title":"Exploitation of natural killer cells for the treatment of acute leukemia","volume":"127","author":"Handgretinger","year":"2016","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3324\/haematol.2009.019539","article-title":"CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect","volume":"95","author":"McLarnon","year":"2010","journal-title":"Haematologica"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1182\/blood-2008-04-151969","article-title":"High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow","volume":"113","author":"Melenhorst","year":"2009","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.immuni.2021.03.001","article-title":"Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes","volume":"54","author":"Ehx","year":"2021","journal-title":"Immunity"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-018-0715-9","article-title":"Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation","volume":"58","author":"Langenhorst","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJM199501193320303","article-title":"Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy","volume":"332","author":"Mackall","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2362.2005.01499.x","article-title":"Age-related thymic activity in adults following chemotherapy-induced lymphopenia","volume":"35","author":"Sfikakis","year":"2005","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1200\/JCO.1995.13.9.2431","article-title":"Infectious and immunosuppressive complications of purine analog therapy","volume":"13","author":"Cheson","year":"1995","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0008-8749(90)90208-9","article-title":"Purine nucleoside modulation of functions of human lymphocytes","volume":"129","author":"Priebe","year":"1990","journal-title":"Cell. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/sj.bmt.1703118","article-title":"Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs. myeloablative regimen","volume":"28","author":"Morecki","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/sj.bmt.1704084","article-title":"A comparison of T-, B- and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors","volume":"32","author":"Petersen","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1080\/10428190500264496","article-title":"Immune recovery after conventional and non-myeloablative allogeneic stem cell transplantation","volume":"46","author":"Schulenburg","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbmt.2014.11.674","article-title":"Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: Thymoglobulin versus alemtuzumab","volume":"21","author":"Willemsen","year":"2015","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3109\/14653249.2012.715243","article-title":"Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation","volume":"14","author":"Bosch","year":"2012","journal-title":"Cytotherapy"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41409-022-01620-x","article-title":"Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: A registry study from the Chronic Malignancies Working Party of the EBMT","volume":"57","author":"Forcade","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1182\/blood-2024-200207","article-title":"Survival Impact of Early Versus Late Discontinuation of Immunosuppression after Allogeneic Stem Cell Transplantation","volume":"144","author":"Laporte","year":"2024","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","article-title":"Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: A retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party","volume":"25","author":"Schmid","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41409-021-01464-x","article-title":"Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): A prospective study from the Belgian Hematology Society (BHS)","volume":"57","author":"Graux","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Proserpio, V. (2019). Differential Expression Analysis in Single-Cell Transcriptomics. Single Cell Methods: Sequencing and Proteomics, Springer.","DOI":"10.1007\/978-1-4939-9240-9"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15691","article-title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia\u2014A matched pair analysis by the Acute Leukaemia Working Party of EBMT","volume":"184","author":"Schmid","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bmt.2015.234","article-title":"Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation","volume":"51","author":"Jedlickova","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1158\/1078-0432.CCR-20-1104","article-title":"Effects of Acute and Chronic Graft-versus-myelodysplastic Syndrome on Long-term Outcomes Following Allogeneic Hematopoietic Cell Transplantation","volume":"26","author":"Konuma","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.bbmt.2016.02.003","article-title":"Addition of 10-Day Decitabine to Fludarabine\/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses","volume":"22","author":"Cruijsen","year":"2016","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41409-022-01645-2","article-title":"Comparative analysis of Decitabine intensified BUCY2 and BUCY2 conditioning regimen for high-risk MDS patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Zhang","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/s41375-018-0123-z","article-title":"Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease","volume":"32","author":"Choi","year":"2018","journal-title":"Leukemia"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/6\/319\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:43:47Z","timestamp":1760031827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/6\/319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":120,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["curroncol32060319"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32060319","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}